Immungene Looks East for $9M Series A

By Marie PowersStaff Writer

Thursday, November 7, 2013

Immungene Inc. landed a $9 million Series A round from Ally Bridge Group, a health care investment firm with offices in Hong Kong and the U.S., to advance its antibody-cytokine fusion technology platform targeting cancer therapies.